



261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis



Client Name: Gaston Weed Company

License Number: MANU0044



Sample ID: VT13081

Sample Name: Bouquet


Sample Lot: MANU0044-130-BOUQ

Sample Matrix: Solvent Extraction Concentrates

Date Received: 9/9/2024

Date Reported: 9/12/2024

Date Tested: 9/11/2024



Total Terpenes (%) : 5.7295

Dominant Terpenes (%)

beta-caryophyllene	2.4585
alpha-Humulene	0.892
Limonene	0.7389
Linalool	0.5439
alpha-Bisabolol	0.3744

Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #39981

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.3744	3.744	0.000003	0.001
alpha-Humulene	0.892	8.92	0.000002	0.001
alpha-Pinene	0.2105	2.105	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	ND	ND	0.000004	0.001
beta-caryophyllene	2.4585	24.585	0.000004	0.001
beta-Pinene	0.0777	0.777	0.000002	0.001
Camphene	0.0338	0.338	0.000001	0.001
Caryophyllene Oxide	0.0306	0.306	0.000011	0.001
Eucalyptol	ND	ND	0.000002	0.001
gamma-Terpinene	< LOQ	< LOQ	0.000002	0.001
Geraniol	< LOQ	< LOQ	0.000008	0.003
Guaiol	0.0502	0.502	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.7389	7.389	0.000002	0.001
Linalool	0.5439	5.439	0.000003	0.001
Nerolidol	0.0991	0.991	0.000007	0.001
Myrcene	0.1989	1.989	0.000003	0.001
Ocimene	0.021	0.21	0.000002	0.001
Total Terpenes	5.7295	57.295		

Callie Chapman

Callie Chapman
Lab Director
9/12/2024

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

